Table 2.

Select ongoing clinical trials with novel combinations

AgentCombinationPhaseLine of therapyIdentifier
Polatuzumab Rituximab and lenalidomide Relapsed NCT02600897 
Polatuzumab Obinutuzumab, rituximab, venetoclax Relapsed NCT02611323 
Polatuzumab R-EPOCH Frontline NCT04231877 
Polatuzumab ± RGemOx Relapsed NCT04182204 
Polatuzumab + R-CHOP vs + R-CHP Frontline NCT04332822 
Venetoclax Obinutuzumab, lenalidomide, ibrutinib, prednisone Relapsed NCT03223610 
Venetoclax Rituximab and ibrutinib Relapsed NCT03136497 
Venetoclax Obinutuzumab and lenalidomide Relapsed NCT02992522 
Venetoclax Obinutuzumab Relapsed NCT02987400 
Venetoclax Rituximab and bortezomib Relapsed NCT02987400 
Venetoclax Rituximab and idasanutlin 1/2 Relapsed NCT03135262 
Venetoclax RICE 1/2 Relapsed NCT03064867 
Selinexor RICE Relapsed NCT02471911 
Selinexor RGDP or RDHAOx 1b Relapsed NCT02741388 
Selinexor Ibrutinib Relapsed NCT02303392 
Selinexor Venetoclax Relapsed NCT03955783 
Selinexor R-CHOP 1b Frontline NCT031478850 
AgentCombinationPhaseLine of therapyIdentifier
Polatuzumab Rituximab and lenalidomide Relapsed NCT02600897 
Polatuzumab Obinutuzumab, rituximab, venetoclax Relapsed NCT02611323 
Polatuzumab R-EPOCH Frontline NCT04231877 
Polatuzumab ± RGemOx Relapsed NCT04182204 
Polatuzumab + R-CHOP vs + R-CHP Frontline NCT04332822 
Venetoclax Obinutuzumab, lenalidomide, ibrutinib, prednisone Relapsed NCT03223610 
Venetoclax Rituximab and ibrutinib Relapsed NCT03136497 
Venetoclax Obinutuzumab and lenalidomide Relapsed NCT02992522 
Venetoclax Obinutuzumab Relapsed NCT02987400 
Venetoclax Rituximab and bortezomib Relapsed NCT02987400 
Venetoclax Rituximab and idasanutlin 1/2 Relapsed NCT03135262 
Venetoclax RICE 1/2 Relapsed NCT03064867 
Selinexor RICE Relapsed NCT02471911 
Selinexor RGDP or RDHAOx 1b Relapsed NCT02741388 
Selinexor Ibrutinib Relapsed NCT02303392 
Selinexor Venetoclax Relapsed NCT03955783 
Selinexor R-CHOP 1b Frontline NCT031478850 

R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHP, rituximab, cyclophosphamide, doxorubicin, and prednisone; RDHAOx, rituximab dexamethasone, cytarabine, and oxaliplatin; R-EPOCH, rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; RGDP, rituximab, gemcitabine, dexamethasone, and cisplatin; RGemOx, rituximab, gemcitabine, and oxaliplatin; RICE, rituximab, ifosfamide, etoposide, and carboplatin.

Close Modal

or Create an Account

Close Modal
Close Modal